Part 2 of 6—A Pharmaceutical Industry Insider’s Claims of Massive Fraud Against 340B Providers
Editor’s note: We invited Bristol Myers Squibb (BMS), which bought Celgene in November 2019, to respond to allegations of illegal or questionable conduct by Celgene with respect to its myeloma drugs and the 340B program. BMS said: “Bristol Myers Squibb has been working to integrate its 340B data systems, policies and functions after acquiring Celgene in late 2019. The IMiD’s [immunomodulatory imide drugs, the class of drugs that includes Thalomid and its analogues Revlimid and Pomalyst] existing limited distribution network complies with the law; it was audited by the Health Resources and Services Administration (HRSA) with no adverse findings, it does not discriminate against 340B covered entities and it supports compliance with the Food and Drug Administration’s (FDA) strict Risk Evaluation and Mitigation Strategies (REMS) safety protocols for these products. To date, HRSA has not communicated any required changes in these practices to BMS. Revlimid, Pomalyst, and Thalomid are widely available to patients. Any patient having difficulty accessing or affording their medicine should contact BMS patient support here.”
Editor’s note: We invited Bristol Myers Squibb (BMS), which bought Celgene in November 2019, to respond to allegations of illegal or questionable conduct by Celgene with respect to its myeloma drugs and the 340B program. BMS said: “Bristol Myers Squibb has been working to integrate its 340B data systems, policies and functions after acquiring Celgene in late 2019. The IMiD’s [immunomodulatory imide drugs, the class of drugs that includes Thalomid and its analogues Revlimid and Pomalyst] existing limited distribution network complies with the law; it was audited by the Health Resources and Services Administration (HRSA) with no adverse findings, it does not discriminate against 340B covered entities and it supports compliance with the Food and Drug Administration’s (FDA) strict Risk Evaluation and Mitigation Strategies (REMS) safety protocols for these products. To date, HRSA has not communicated any required changes in these practices to BMS. Revlimid, Pomalyst, and Thalomid are widely available to patients. Any patient having difficulty accessing or affording their medicine should contact BMS patient support here.”
Part 1 of this investigative series was free, but only paid subscribers will be able to access the remaining five parts.
If you are not a paid subscriber, take advantage of our lowest-ever discount opportunity: 25% off our regular subscription rates, only available through June 11. Subscribe now using coupon code INVESTIGATE25. For questions, please contact reshma.eggleston@340breport.com.
If you are already a paid subscriber, please follow the steps below.
